Kymera Therapeutics KYMR EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Kymera Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's EBITDA margin?
- Kymera Therapeutics (KYMR) reported EBITDA margin of -681.6% in Q1 2026.
- How has Kymera Therapeutics's EBITDA margin changed year-over-year?
- Kymera Therapeutics's EBITDA margin decreased by 48.5% year-over-year, from -459% to -681.6%.
- What is the long-term trend for Kymera Therapeutics's EBITDA margin?
- Over 5 years (2020 to 2025), Kymera Therapeutics's EBITDA margin has grown at a 46.1% compound annual growth rate (CAGR), from -130.9% to -869.9%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.